CDA | Evidence Driven
CDA | Evidence Driven

dabrafenib trametinib

Details

Generic Name:
dabrafenib trametinib
Project Status:
Cancelled
Therapeutic Area:
Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation
Call for patient/clinician input open:
Brand Name:
Tafinlar-Mekinist
Project Line:
Reimbursement Review
Project Number:
PC0337-000
Call for patient/clinician input closed:
Tumour Type:
Head and Neck
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Dabrafenib-trametinib (D-T) for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Submission Type:
Drug Plan Initiated
Fee Schedule:
Pending
Indications:
Dabrafenib-trametinib (D-T) for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : November 10, 2023